GlassScriptPhysician profile
Yale R Smith
NPI 1619941440
$10,069.44
in general payments reported to CMS, 2019-2025
46 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.98 · 2021: $315 · 2022: $2,485 · 2023: $2,399 · 2024: $3,019 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,244.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,054.12 | 2022-2025 | Reblozyl, Abecma, Opdivo |
| Astrazeneca Pharmaceuticals LP | $836.64 | 2022-2025 | Tagrisso, Enhertu, Lynparza |
| Regeneron Healthcare Solutions, INC. | $662.02 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $646.73 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $531.55 | 2022-2025 | |
| Incyte Corporation | $531.27 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $398.62 | 2022-2025 | Enhertu, Vanflyta |
| Janssen Biotech, INC. | $380.86 | 2021-2024 | Rybrevant |
| Kite Pharma, INC. | $368.00 | 2022-2024 | Yescarta |
| Mirati Therapeutics, INC. | $295.41 | 2023-2024 | Krazati |
| Eisai INC. | $277.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.30 | 2021-2025 | Iclusig, Ninlaro |
| Glaxosmithkline, LLC. | $249.44 | 2024-2025 | Ojjaara |
| Genentech USA, INC. | $249.23 | 2022-2023 | Lunsumio |
| Amgen INC. | $248.92 | 2023 | Lumakras, Kyprolis |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yale Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.